IPO Day With Absci CEO Sean McClain – The Google Of Synthetic Biology (Video)

Summary:

• Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.
• CEO Sean McClain discusses the emotion around going public, acquisitions in the time of Covid and being a technology driven company.
• Providing tech solutions for pharma partners and what metric is key to watch over the next year.

Absci (NASDAQ:ABSI), going public today, is a synthetic biology company whose platform technology aids in the drug discovery process. With its AI-powered Integrated Drug Creation Platform, Absci enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. CEO Sean McClain joined us earlier today to discuss the emotion around going public, acquisitions in the time of Covid and being a technology driven company. Number of new programs signed up is the key metric to watch over the coming year.